TABLE 8Composition of Commonly Used Crystalloids^{1,2,3,4}

	Osmolarity (mOsm/L)	рН	Na (mEq/L)	CI (mEq/L)	K (mEq/L)	Mg (mEq/L)	Ca (mEq/L)	Dextrose (g/L)	Buffers
REPLACEMENT CRYSTALLOID FLUIDS									
Hypertonic Crystalloids									
3% NaCl	1027	5.0	513	513	0	0	0	0	None
5% NaCl	1711	5.0	856	856	0	0	0	0	None
7.5% NaCl	2566	5.0	1293	1293	0	0	0	0	None
23.4% NaCl	8008	5.0	4004	4004	0	0	0	0	None
Isotonic Crystalloids									
0.9% NaCl	308	5.0	154	154	0	0	0	0	None
Plasma-Lyte A	294	7.4	140	98	5	3	0	0	Acetate, Gluconate
Plasma-Lyte 148	294	5.5	140	98	5	3	0	0	Acetate, Gluconate
Normosol R	294	5.5	140	98	5	3	0	0	Acetate, Gluconate
Lactated Ringer's	275	6.5	130	109	4	0	3	0	Lactate
MAINTENANCE CRYSTALLOID FLUIDS									
Hypotonic Crystalloids									
Plasma-Lyte 56 in 5% dextrose	363	3.5-6	40	40	13	3	0	50	Acetate
0.45% NaCl	154	5.6	77	77	0	0	0	0	None
0.45 NaCl in 2.5% dextrose	280	4.5	77	77	0	0	0	25	None
5% dextrose in water	252	4.0	0	0	0	0	0	50	None
Normosol M in 5% dextrose	363	5.0	40	40	13	3	0	50	None

- 1. Rudloff E, Hopper K. 2021. Crystalloid and colloid compositions and their impact. Frontiers in Veterinary Science. 8:639848.
- 2. Strandvik GF. 2009. Hypertonic saline in critical care: a review of the literature and guidelines for use in hypotensive states and raised intracranial pressure. *Anaesthesia*. 64(9):990-1003
- 3. Holden D, et al. 2023. Hypertonic saline use in neurocritical care for treating cerebral edema: A review of optimal formulation, dosing, safety, administration and storage. *American Journal of Health-System Pharmacy*. 80(6):331-342.
- 4. Carr CJ, et al. 2021. An audit and comparison of pH, measured concentration, and particulate matter in mannitol and hypertonic saline solutions. *Frontiers in Neurology*. 12:667842.

